Thomas M D, Cormack R, Tempany C M, Kumar S, Manola J, Schneider L, Hurwitz M D, D'Amico A V
Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):905-8. doi: 10.1016/s0360-3016(00)00541-1.
Larger prostate gland volumes have been associated with long-term urinary morbidity in prostate interstitial radiation therapy utilizing ultrasound image guidance technique. This study was performed to identify the clinical and technical predictors of acute urinary retention following magnetic-resonance (MR)-guided prostate interstitial brachytherapy.
Fifty patients underwent MR-guided prostate brachytherapy between December 1997 and March 1999. Patient selection was limited to men with stage T1cNXM0 disease, PSA of less than10 ng/mL, biopsy Gleason score not more than 3 + 4, and endorectal coil MR stage T2 disease. Dosimetry plans were developed in the operating room and (125)Iodine sources were implanted using MR real-time guidance. The peripheral zone (PZ) of the prostate gland was defined as the clinical target volume (CTV) and the minimum prescribed dose to the CTV was 137 Gy. The volumes of the PZ, transition zone (TZ), and total prostate gland volume were also determined by MR. Individual source strength ranged from 0.35 to 0.54 microGym(2)/h (NIST 99, median 0.46 microGym(2)/h) and the total implanted activity ranged from 17.0 to 43.1 mCi (median, 28.1 mCi) using 43-120 seeds (median, 79). The seeds were placed using MR-compatible biopsy needles (14-28, median, 19).
The ability of clinical (MR defined prostate, PZ, and TZ volumes) and technical (number of catheters, number of seeds implanted, and total activity) factors to predict AUR for 50 men undergoing MR-guided prostate interstitial brachytherapy were evaluated using univariable and logistic regression multivariable analyses. Six men (12%) experienced AUR within 24 h after removal of the Foley catheter subsequent to prostate brachytherapy. The total number of seeds (p = 0.05), MR determined prostate volume (p < 0.01), and the MR-determined TZ volume (p < 0.01) were significant predictors of AUR on univariable analysis. Utilizing a multivariable logistic regression analysis, the TZ volume was the only significant predictor of AUR (p < 0.01). The prostate volume is highly correlated to the TZ volume (Spearman correlation coefficient of 0. 91) and was thus significant in the univariable analysis; however, the prostate volume did not add prognostic value in multivariable analysis.
Benign prostatic hyperplasia (BPH) resulting in an enlarged TZ volume, is the most important predictor of AUR following MR-guided prostate interstitial radiation therapy. Although AUR was significant (60%) in men with moderate BPH (TZ volume >/= 50 cc), it was also self-limiting.
在利用超声图像引导技术的前列腺间质放射治疗中,前列腺体积较大与长期泌尿系统发病率相关。本研究旨在确定磁共振(MR)引导下前列腺间质近距离放射治疗后急性尿潴留的临床和技术预测因素。
1997年12月至1999年3月期间,50例患者接受了MR引导下的前列腺近距离放射治疗。患者选择限于T1cNXM0期疾病、前列腺特异性抗原(PSA)小于10 ng/mL、活检Gleason评分不超过3 + 4且直肠内线圈MR分期为T2期疾病的男性。在手术室制定剂量计划,并使用MR实时引导植入碘-125源。前列腺外周区(PZ)被定义为临床靶区(CTV),CTV的最小处方剂量为137 Gy。PZ、移行区(TZ)和前列腺总体积也通过MR确定。单个源强度范围为0.35至0.54微居里(2)/小时(NIST 99,中位数0.46微居里(2)/小时),使用43 - 120颗种子(中位数79颗)时,总植入活度范围为17.0至43.1毫居里(中位数28.1毫居里)。种子通过与MR兼容的活检针(14 - 28,中位数19)放置。
使用单变量和逻辑回归多变量分析评估临床(MR定义的前列腺、PZ和TZ体积)和技术(导管数量、植入种子数量和总活度)因素预测50例接受MR引导下前列腺间质近距离放射治疗男性发生急性尿潴留(AUR)的能力。6名男性(12%)在前列腺近距离放射治疗后拔除Foley导管后24小时内发生AUR。在单变量分析中,种子总数(p = 0.05)、MR测定的前列腺体积(p < 0.01)和MR测定的TZ体积(p < 0.01)是AUR的显著预测因素。使用多变量逻辑回归分析,TZ体积是AUR的唯一显著预测因素(p < 0.01)。前列腺体积与TZ体积高度相关(Spearman相关系数为0.91),因此在单变量分析中具有显著性;然而,在多变量分析中前列腺体积并未增加预后价值。
导致TZ体积增大的良性前列腺增生(BPH)是MR引导下前列腺间质放射治疗后AUR的最重要预测因素。尽管中度BPH(TZ体积≥50 cc)男性中AUR发生率较高(60%),但它也是自限性的。